Latest News

Final analysis results from the phase 3 LEAP-017 trial demonstrated that lenvatinib plus pembrolizumab did not significantly improve overall survival compared to standard of care among patients with previously treated mismatch repair...

Phase 2 results from the SELECT study demonstrated that weekly carfilzomib, pomalidomide, and dexamethasone treatment showed efficacy and tolerability among patients with relapsed/refractory multiple myeloma.

According to a phase 2 study, selumetinib demonstrated efficacy among both children and adults with NF1 and inoperable plexiform neurofibromas, and in other manifestations.

Long-term results from the phase 2 ATEMPT trial demonstrated that adjuvant trastuzumab emtansine improved long-term outcomes among patients with HER2-positive early-stage breast cancer.

A retrospective analysis demonstrated that post-transplantation cyclophosphamide yielded survival and non-relapse mortality benefit compared to anti-thymocyte globulin treatment for GVHD prophylaxis among patients undergoing allogeneic stem...

Findings from the real-world CASSIOPEA study show the considerable disease burden of neurofibromatosis type 1 with plexiform neurofibromas (NF1-PN) highlighting the importance of effective treatments for this patient population.

Findings from a phase 2 study show vinblastine/methotrexate did not demonstrate activity for neurofibromatosis type 1 with plexiform neurofibromas (NF1-PN) in pediatric and young-adult patients, despite being well-tolerated.

Study findings show neurofibromatosis type 1 with plexiform neurofibromas (NF1-PN) worsens adult patient and caregiver health-related quality of life vs that of the general population.

The FDA has approved the new drug application for SH-105, a liquid formulation of thiotepa, for the treatment of patients with breast and ovarian cancer.

Among pediatric patients with neurofibromatosis type 1 with plexiform neurofibromas (NF1-PN), treatment with selumetinib resulted in significant shrinkage in PN without any clinically significant morbidity.